{
  "id": 12321244,
  "title": "Paris-based WhiteLab Genomics raises €23.2 million to accelerate AI-driven genomic medicine development",
  "url": "https://urgent.news/2026/10/06/paris-based-whitelab-genomics-raises-23-2-million-to-accelerate-ai",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-06T06:28:31.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/10/paris-based-whitelab-genomics-raises-e23-2-million-to-accelerate-ai-driven-genomic-medicine-development/"
  },
  "original_language": "en",
  "account": "Paris-based WhiteLab Genomics, a biotech company utilizing artificial intelligence to design genomic medicines, has secured €23.2 million ($26 million) in Series B funding. The investment round was spearheaded by AVP, a global investment firm managing €2.5 billion in assets, alongside participation from new investors Yaday Health and Blast Club, as well as existing backers Omnes Capital and Debiopharm Innovation Fund. David Del Bourgo, co-founder and CEO of WhiteLab Genomics, stated that the company's AI-driven approach designs genomic medicines that function in vivo, rather than just on paper, marking a significant impact on the field. The funds will be utilized to expand in vivo validation efforts, strengthen partnerships in North America, and explore opportunities in Japan and South Korea.",
  "summary": "WhiteLab Genomics, a Paris-based BioTech company that uses AI to design the building blocks of genomic medicines, has closed a €23.2 million ($26 million) Series B funding round. The round was led by AVP, an independent global investment platform managing over €2.5 billion in assets. The round also saw participation from new investors Yaday Health […] The post Paris-based WhiteLab Genomics raises…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}